Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

Summary

This is a multicenter, open-label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with relapsed or refractory sarcoma and osteosarcoma.

Eligibility

Inclusion Criteria:

* Age ≥12 and ≤40 years.
* Histologically confirmed relapsed or refractory sarcoma (Phase 1) or osteosarcoma (Phase 2).
* At least one prior standard systemic therapy regimen.
* Not candidates for available therapies known to provide survival benefit.
* Karnofsky/Lansky performance score ≥60.
* Life expectancy ≥16 weeks.
* Adequate organ function: ANC ≥1,000/mcL, Platelets ≥100,000/uL, Hemoglobin ≥8 g/dL, Adequate hepatic and renal function.
* Ability to swallow tablets.
* Negative pregnancy test for females of childbearing potential.
* Agreement to use effective contraception.
* Ability to provide informed consent/assent.

Exclusion Criteria:

* Receiving another investigational agent.
* Receiving concurrent anticancer therapy.
* Known hypersensitivity to domatinostat or sirolimus.
* Bone marrow-only disease.
* CNS metastatic disease.
* Major surgery within 2 weeks prior to treatment.
* Active malignancy within the previous 3 years (with protocol-specified exceptions).
* History of solid organ transplantation.
* Significant recent cardiac disease.
* Concurrent prohibited CYP3A4/P-gp interacting medications.
* Uncontrolled infection or other serious uncontrolled illness.
* Pregnancy or breastfeeding.
* HIV infection on antiretroviral therapy.
* Weight \<40 kg.
* Inability to comply with study requirements.

Conditions3

Interventions2

Locations4 sites

Find trials near these locations

Related trials

• Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies — Federal Research Institute of Pediatric Hematology, Oncology and Immunology
• Methods of T Cell Depletion Trial (MoTD) — University of Birmingham
• Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia — Chinese SLE Treatment And Research Group
• The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus — Tongji Hospital
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study — Darcy Krueger
• 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome — City of Hope Medical Center
• The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation — National Cancer Institute (NCI)
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer — National Cancer Institute (NCI)

Browse More Trials